- Home
- PCB vs AUTL Comparison
PCB vs AUTL Comparison
Compare PCB & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCB | AUTL |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | 752 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 410.1M | 385.9M |
| IPO Year | 2018 | 2025 |
Fundamental Metrics
Financial Performance| Metric | PCB | AUTL |
|---|---|---|
| Price | $27.50 | $1.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $25.50 | $8.50 |
| AVG Volume (30 Days) | 41.4K | ★ 1.1M |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | ★ 48.28 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | $2,899,000.00 | ★ $10,120,000.00 |
| Revenue This Year | $13.73 | $80.32 |
| Revenue Next Year | $9.07 | $53.96 |
| P/E Ratio | $39.01 | ★ N/A |
| Revenue Growth | 4.51 | ★ 496.00 |
| 52 Week Low | $19.70 | $1.18 |
| 52 Week High | $30.84 | $2.60 |
Technical Indicators
Market Signals| Indicator | PCB | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 46.35 | 45.27 |
| Support Level | $21.10 | $1.37 |
| Resistance Level | $29.29 | $1.52 |
| Average True Range (ATR) | 0.89 | 0.10 |
| MACD | -0.23 | -0.01 |
| Stochastic Oscillator | 16.10 | 24.66 |
Price Performance
Historical ComparisonAbout PCB PCB Bancorp
PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals. The company provided it's services in Los Angeles and Orange Counties, California; Bellevue, Washington; and Atlanta, Georgia.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.